Table 1 Patient characteristics
From: Proteomic analysis identifies subgroups of patients with active systemic lupus erythematosus
Total (n = 223) | No (%)/median (IQR) |
|---|---|
Age, years (n = 197) | 40 (30, 51) |
Female | 198 (88.8) |
Caucasian (n = 222) | 132 (59.2) |
Current smoker | 27 (12.1) |
Disease duration, years (n = 218) | 10 (6, 17) |
SLICC damage index (n = 206) | 0 (0,1) |
1997 ACR criteria at baseline (n = 203) |  |
 Number fulfilling ≥ 4 criteria | 186 (83.4) |
 Malar rash | 122 (54.7) |
 Photosensitivity | 115 (51.6) |
 Discoid rash | 41 (18.4) |
 Oral ulcers | 136 (61) |
 Arthritis | 192 (86.1) |
 Serositis | 69 (30.9) |
 CNS | 22 (9.9) |
 Renal disease | 81 (36.3) |
 Haematologic disorder | 115 (51.6) |
 Immunologic disorder | 151 (67.7) |
 Positive ANA | 185 (83) |
Disease activity | Â |
 SLEDAI score (n = 212) | 8 (4.5, 14) |
 SLICC damage index (n = 206) | 0 (0,1) |
BILAG-2004 score at baseline | Â |
 Constitutional | 19 (9.3) |
 Mucocutaneous | 107 (51.2) |
 Neuropsychiatric | 23 (11.2) |
 Musculoskeletal | 95 (45.5) |
 Cardiorespiratory | 35 (17) |
 Gastrointestinal | 11 (5.4) |
 Ophthalmic | 13 (6.4) |
 Renal | 79 (37.4) |
 Haematological | 9 (4.4) |
 Baseline creatinine, umol/l (n = 162) | 66 (57, 78) |
 BMI, kg/m2 (n = 171) | 26.4 (22.9, 31.3) |
Medications | Â |
 Current steroid use | 136 (61) |
 Usual daily OCS dose (mg/day) | 10 (5, 14) |
 Current anti-malarial use | 110 (49.3) |
 Anti-malarial use ever | 202 (90.6) |
 Methotrexate | 9 (4) |
 Azathioprine | 11 (4.9) |
 Mycophenolate mofetil | 77 (34.5) |
 Calcineurin inhibitor | 3(1.3) |
Serology | Â |
 Ro (n = 215) | 76 (35.3) |
 Ro52 (n = 215) | 42 (18.8) |
 Ro60 (n = 192) | 70 (31.4) |
 La (n = 195) | 19 (8.5) |
 dsDNA (n = 215) | 87 (39) |
 dsDNA titre, IU/l | 38.5 (13.9, 246.1) |
 U1-RNP (n = 192) | 56 (25.1) |
 Low C3/C4 (n = 212) | 100 (44.8) |